Document:

exv10w1

Exhibit 10.1

[TeleTech Holdings, Inc. Letterhead]

Employment Agreement of Gregory G. Hopkins

VIA E-MAIL

Mr. Greg Hopkins

Dear Greg:

We are pleased to offer you employment as our senior executive deal hunter reporting to Ken
Tuchman. We anticipate a start date of no later than April 6, 2004. This offer is conditional
upon approval of the Company’s Board of Directors, approval we expect to secure.

The specific terms of your employment are as follows: (i) annual base salary of $275,000; (ii) a
target annual incentive opportunity of 100% of your base salary with an additional stretch target
of 150% of your base salary. Your incentive compensation will be based on performance goals set by
you and Ken. For 2004, these goals will be set within the first two weeks of your start date. For
2005 and beyond, these goals will be set at the end of the previous year(s); (iii) a signing bonus
of $200,000, to be paid in your first week of employment (subject to customary tax withholdings);
(iv) an award of 300,000 stock options at an exercise price equal to the closing price of the
Company’s stock on your first day of employment. The grant will vest in equal annual installments
over a four (4) year period, subject to your continued employment with the Company. In the event
there is a “change in control” as defined in the TeleTech stock option plan, all options you hold
will vest upon the Change in Control; (v) the Company’s executive benefits package, which includes
four (4) weeks of vacation annually accrued per Company policy, medical, dental, life and
disability insurance. The Company will pay all premiums associated with these insurance policies.
Subject to your satisfactory completion of a standard medical examination, the Company will
purchase a term life policy having a face value of $4 Million; and (vi) your eligibility to
participate in the Company’s 401(k), Deferred Compensation and Employee Stock Purchase Plans, as
well as other plans made available by TeleTech to its employees from time to time.

Additionally, if the Company terminates your employment without “cause,” after you execute a
separation agreement the Company shall pay you severance compensation equal to the sum of six
months of your then-current base salary, which shall be payable bi-weekly or in a lump sum as
mutually agreed, less legally required withholdings, on the first of the month following the
termination date. For purposes of this letter, “cause” exists if you engage in any of the
following: commission of any felony, any crime involving dishonesty or moral turpitude, or any law
or ethical rule relating to the Company; theft or misuse of TeleTech’s property, violation of the
Company’s Code of Conduct; illegal use of any controlled substance; unauthorized use or disclosure
of trade secrets or other confidential information of the Company; discriminatory or harassing
behavior, whether or not illegal under federal, state or local law; willful misconduct in
connection with your duties; or failure to perform your job duties in a satisfactory manner after
you have been given 30 days written notice signed by the Human Resources Department that
performance must be improved and, after receiving that notice, you have failed to improve
performance.

 

 

TeleTech also requires its executives to sign an Agreement to Protect Confidential Information,
Assign Inventions, and Prevent Unfair Competition and Unfair Solicitation. I have included this
Agreement for your review. This offer also is contingent upon your successful clearance of
TeleTech’s background and drug screens, and our successful completion of reference checking.

On behalf of Ken and Jim, we are thrilled with the prospect of your coming on board.

	 	 	 	 	 
	 	Sincerely,

 	 
	 	/s/ John R. Simon
 	 
	 	John R. Simon 	 
	 	SVP, Human Resources 	 
	 
	 	Agreed to and accepted:

 	 
	 	/s/ Greg Hopkins
 	 
	 	Greg Hopkinsexv10w1

EXHIBIT 10.1

AMENDMENT 1

To

MANUFACTURING AND SUPPLY AGREEMENT

Between

ALTUS PHARMACEUTICALS INC.

And

LONZA LTD.

          THIS AMENDMENT NO. 1 (the “Amendment”) effective as of June 30, 2008 (the “Effective Date”),
is between by and between Altus Pharmaceuticals Inc., a Delaware corporation with its principal
place of business located at 640 Memorial Drive, Cambridge, MA 02139 (“Altus”), and Lonza
Ltd, a Swiss corporation having offices at Muenchensteinerstrasse 38, CH-4002 Basel,
Switzerland (“Lonza”). Each of Altus and Lonza may be referred to herein individually as a “Party”
and collectively as the “Parties”. All capitalized terms not defined in this Amendment shall have
the same meaning as in the Agreement (defined below).

          WHEREAS, Altus and Lonza are parties to a Manufacturing and Supply Agreement entered into as
of November 16, 2006 (the “Agreement”); and

          WHEREAS, the parties wish to amend the
Agreement (i) to provide for the [***] of [***]
obligation to [***] in [***] and (ii) to [***] the [***] upon which [***] will provide an [***] in
[***] for Bulk Product Components to be manufactured in [***].

          NOW, THEREFORE, in consideration of the premises contained herein and other valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

	1.	 	In the event that Lonza and a [***] a [***] or a [***] to [***] and/or [***] at least a [***]
in each of [***] and [***] in [***] (such [***] to begin approximately during the [***] of
[***], the Parties agree that [***] obligation [***] the [***] of [***] and the [***] of [***]
in [***], as set forth in Section 3.3 of the Agreement
is hereby [***] until [***] (the
“[***]”). Such [***] shall be added to [***] obligations to [***] in [***]. In addition,
[***] shall have [***] under Section 6.2(c) to [***] the [***] associated with such [***].
	 
	2.	 	The Parties agree that Altus may provide the [***] due in the [***] of [***] on [***] instead
of on [***].
	 
	3.	 	Upon execution, this Amendment 1 shall be made a part of the Agreement and shall be
incorporated by reference. Except as provided herein, all other terms and conditions of the
Agreement shall remain in full force and effect.

[Signatures appear on the following page]

Portions
of this Exhibit are omitted and have been filed separately with the
Secretary of the Commission
pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2
of the Exchange Act.

 

 

          IN WITNESS WHEREOF, the parties hereto have executed or caused this Amendment No. 1 to be
executed by their respective officers or other representatives duly authorized.

	 	 	 	 	 	 	 
	Altus Pharmaceuticals Inc. 	 	Lonza Ltd 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Jill E. Porter
	 	By:
	 	/s/ Thomas Keppler
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	Jill E. Porter
	 	Name:
	 	Thomas Keppler
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Title:

	 	Vice President, Process Development
	 	Title:
	 	Head of Patent Department
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	July 24, 2008
	 	By:
	 	/s/ Yves Kesch
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Name:
	 	Yves Kesch
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Legal Counsel
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Date:
	 	17 July 2008
	 

	 	 	 	 	 	 

-2-

Portions
of this Exhibit are omitted and have been filed separately with the
Secretary of the Commission
pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2
of the Exchange Act.exv10w2

EXHIBIT 10.2

Execution Copy

AMENDMENT 2

To

MANUFACTURING AND SUPPLY AGREEMENT

Between

ALTUS PHARMACEUTICALS INC.

And

LONZA LTD.

          THIS AMENDMENT 2 (the “Amendment”) effective as of August 19, 2008 (the “Effective Date”), is
between by and between Altus Pharmaceuticals Inc., a Delaware corporation with its principal place
of business located at 640 Memorial Drive, Cambridge, MA 02139 (“Altus”), and Lonza Ltd, a Swiss
corporation having offices at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (“Lonza”).
Each of Altus and Lonza may be referred to herein individually as a “Party” and collectively as the
“Parties”. All capitalized terms not defined in this Amendment shall have the same meaning as in
the Agreement (defined below).

          WHEREAS, Altus and Lonza are parties to a Manufacturing and Supply Agreement entered into as
of November 16, 2006, as amended pursuant to Amendment 1 thereto (as so amended, the “Agreement”);
and

          WHEREAS, the parties wish to amend the Agreement further (i) to provide for certain additional
payments from Altus to Lonza and (ii) to establish a [***] for the timing of the [***] and the
costs associated with any changes to [***].

          NOW, THEREFORE, in consideration of the premises contained herein and other valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

	1.	 	The Parties acknowledge that the manufacture of the [***] of [***] has been completed, that
the manufacture of the [***] of [***] has been initiated and that additional work has been
performed by Lonza with regard to the [***]. Altus agrees to make an additional payment to
Lonza (a) for the time between the [***] of the [***] and the [***] of the [***] of [***] and
(b) for [***] of work undertaken in connection with the [***] of [***], in the amount of [***]
within thirty (30) days of the date upon which both parties have executed this Amendment.
	 
	2.	 	The Parties have established a joint steering committee (the “Joint Steering Committee”) in
order to fulfill the objectives of the Agreement and to create a forum for communication
relating to activities being undertaken pursuant to the Agreement. The Joint Steering
Committee will discuss and agree on the appropriate amount of time between completion of the
[***] and the initiation of the [***] for [***] (the “Agreed-to Interim Period”). In the
event that there is a [***] in [***] the [***] of the [***] for the [***] beyond the Agreed-to
Interim Period, the Joint Steering Committee will promptly determine, prior to the [***] of
[***] such [***], whether the [***] was
caused by [***] or [***]. If the [***] is caused [***]
by [***], then [***] shall pay [***] a [***] fee for [***] of such [***] at the rate set forth
below. In the event that the [***] is caused by [***], then [***] shall pay [***] for [***]
of the [***] caused by [***], less the [***] of [***] for which the [***] is also caused by
[***]. If a [***] is caused by a [***] of the Joint Steering Committee to [***], the [***]
shall be [***] the party or parties causing [***]. For example, if the [***] is [***], of
which [***] are caused [***] and [***] are caused [***], then [***] will [***] the fee for
[***]. As another example, if the [***] is [***], of which [***] are caused [***], but [***]
of [***] are

Portions
of this Exhibit are omitted and have been filed separately with the
Secretary of the Commission
pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2
of the Exchange Act.

 

 

	 	 	[***] caused [***], then [***] will [***] the fee for [***]. The [***] fee payable by [***]
will be [***] [***].
	 
	3.	 	The Parties acknowledge that [***] manufactured an [***] of the [***] in addition to those
originally contemplated in the Agreement in order to [***] of the [***]. [***] agrees to make
an [***] to [***] for such [***] in the amount of [***] within thirty (30) days of the date
upon which both parties have executed this Amendment.
	 
	4.	 	As provided in the Agreement, [***] will manufacture [***] of [***]. For [***], [***] will
[***] to [***] a [***] of [***] upon the [***] of the manufacturing of [***] of such [***] to
[***]. Whether [***] has occurred will be [***] by the [***] of [***] at [***], the [***]
where [***] occurs, and the [***]. The Parties will use [***] to reach agreement on [***]
following completion of the [***]. In the event that the Parties are unable to [***], the
matter shall be submitted to [***]. Such [***] shall determine whether [***], including
without limitation [***], and the parties agree that [***] shall be [***] and [***]. The
Party [***] shall [***] of the [***].
	 
	5.	 	[***] will [***] to [***] a [***] of [***] upon the [***] on or prior to [***] of a [***] by
the [***] with, if necessary, a [***] acceptable
to [***] that (a) addresses any [***] or [***]
required by the [***] and (b) does not [***] the [***] or [***] the [***]. In the event that
the [***] does not perform the [***] on or prior to [***], [***] will in [***] consider a
reasonable [***] of the [***].
	 
	6.	 	Upon execution, this Amendment 2 shall be made a part of the Agreement and shall be
incorporated by reference. Except as provided herein, all other terms and conditions of the
Agreement shall remain in full force and effect and all other payments shall be made solely in
accordance with the Agreement, as amended..

          IN WITNESS WHEREOF, the parties hereto have executed or caused this Amendment 2 to be executed
by their respective officers or other representatives duly authorized.

	 	 	 	 	 	 	 
	Altus Pharmaceuticals Inc. 	 	Lonza Ltd 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Burkhard Blank
	 	By:
	 	/s/ Dr. Michael Petersen
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	Burkhard Blank
	 	Name:
	 	Dr. Michael Petersen
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Title:

	 	Executive Vice President
	 	Title:
	 	Head Bus. Dev. Biochemicals
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	August 18, 2008
	 	By:
	 	/s/ Gerard Romeder
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Name:
	 	Gerard Romeder
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Title:
	 	Director, Sales and Bus. Dev
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	Date:
	 	September 24, 2008
	 

	 	 	 	 	 	 

-2-

Portions
of this Exhibit are omitted and have been filed separately with the
Secretary of the Commission
pursuant to the Registrant’s
application requesting confidential treatment under Rule 24b-2
of the Exchange Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]